Alliance Wealth Advisors LLC UT Grows Holdings in Repligen Co. (NASDAQ:RGEN)

Alliance Wealth Advisors LLC UT raised its stake in Repligen Co. (NASDAQ:RGENFree Report) by 9.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,346 shares of the biotechnology company’s stock after acquiring an additional 210 shares during the period. Alliance Wealth Advisors LLC UT’s holdings in Repligen were worth $373,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the stock. Nichols & Pratt Advisers LLP MA acquired a new position in Repligen in the third quarter valued at $376,000. Kensington Investment Counsel LLC raised its holdings in shares of Repligen by 4.2% in the third quarter. Kensington Investment Counsel LLC now owns 7,730 shares of the biotechnology company’s stock valued at $1,229,000 after buying an additional 312 shares during the last quarter. Wafra Inc. purchased a new stake in shares of Repligen in the third quarter valued at about $8,759,000. Wealth Alliance purchased a new stake in shares of Repligen in the third quarter valued at about $265,000. Finally, Headlands Technologies LLC purchased a new stake in shares of Repligen in the third quarter valued at about $75,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Trading Up 0.3 %

Shares of RGEN stock opened at $205.70 on Tuesday. The company’s fifty day simple moving average is $180.85 and its 200-day simple moving average is $165.87. Repligen Co. has a 52 week low of $110.45 and a 52 week high of $208.16. The company has a market cap of $11.48 billion, a PE ratio of 101.33, a P/E/G ratio of 4.76 and a beta of 1.04.

Analysts Set New Price Targets

Several research analysts recently issued reports on RGEN shares. Benchmark cut shares of Repligen from a “buy” rating to a “hold” rating in a report on Monday, December 4th. JPMorgan Chase & Co. upped their target price on shares of Repligen from $170.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 20th. UBS Group lowered their target price on shares of Repligen from $210.00 to $170.00 and set a “buy” rating on the stock in a research report on Thursday, November 2nd. Royal Bank of Canada lowered their target price on shares of Repligen from $207.00 to $200.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 1st. Finally, KeyCorp lowered their target price on shares of Repligen from $240.00 to $210.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and an average price target of $191.50.

Check Out Our Latest Stock Analysis on RGEN

About Repligen

(Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Read More

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.